TrialStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2013

Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.

C Matuschek et al.PubMed ↗Publisher ↗

No numbers read from the abstract.